Apellis Pharmaceuticals Inc (APLS) Receives Average Recommendation of “Buy” from Analysts

Shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) have been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $38.00.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research cut Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 16th. JPMorgan Chase & Co. decreased their price target on Apellis Pharmaceuticals from $38.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, November 14th. Cantor Fitzgerald set a $53.00 price target on Apellis Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 12th. ValuEngine raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, B. Riley increased their price target on Apellis Pharmaceuticals from $27.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, September 13th.

In other Apellis Pharmaceuticals news, major shareholder Morningside Venture Investment bought 81,323 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The shares were bought at an average price of $19.48 per share, for a total transaction of $1,584,172.04. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel David O. Watson sold 15,776 shares of the company’s stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $18.78, for a total value of $296,273.28. The disclosure for this sale can be found here. Corporate insiders own 9.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Teachers Advisors LLC now owns 72,723 shares of the company’s stock valued at $1,293,000 after purchasing an additional 3,716 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $477,000. Opaleye Management Inc. boosted its position in shares of Apellis Pharmaceuticals by 41.5% during the 3rd quarter. Opaleye Management Inc. now owns 375,000 shares of the company’s stock valued at $6,667,000 after purchasing an additional 110,000 shares in the last quarter. Sphera Funds Management LTD. boosted its position in shares of Apellis Pharmaceuticals by 91.8% during the 3rd quarter. Sphera Funds Management LTD. now owns 212,470 shares of the company’s stock valued at $3,778,000 after purchasing an additional 101,667 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $447,000. Institutional investors own 57.70% of the company’s stock.

Shares of APLS opened at $15.62 on Friday. Apellis Pharmaceuticals has a 12-month low of $11.45 and a 12-month high of $32.00. The company has a quick ratio of 14.91, a current ratio of 14.90 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $878.51 million and a price-to-earnings ratio of -4.26.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. As a group, research analysts forecast that Apellis Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Featured Article: How to Use the New Google Finance Tool

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply